Physician profile
Robert Lamb
NPI 1194710327
$5,560.09
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $1,005 · 2021: $2,043 · 2022: $1,225.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,228.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $963.45 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $535.63 | 2019-2022 | |
| Amgen INC. | $430.91 | 2019-2022 | |
| Horizon Therapeutics Plc | $382.23 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $330.83 | 2021-2022 | |
| Genzyme Corporation | $283.19 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $266.04 | 2021-2022 | |
| Daiichi Sankyo INC. | $249.91 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $198.74 | 2020-2022 | |
| Novo Nordisk INC | $193.45 | 2020-2022 | |
| Amarin Pharma, INC. | $124.68 | 2019 | |
| Intuitive Surgical, INC. | $95.01 | 2020 | |
| Calliditas Therapeutics US INC. | $74.89 | 2022 | |
| Merck Sharp & Dohme LLC | $39.78 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39.08 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $38.33 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $22.13 | 2021 | |
| Lilly USA, LLC | $21.29 | 2022 | |
| Baxter Healthcare | $15.62 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.52 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.